South Korea’s Innovation Leadership at a Crossroads (2025 and Beyond)
South Korea’s rise from a war-torn nation in the 1950s to a global technological powerhouse is nothing short of
The Polygenic Prophet: Hype and Reality of Polygenic Risk Scores
Polygenic risk scores (PRS) are the latest oracle in healthcare’s quest to predict fate. The basic idea sounds beguilingly
The Outsourcing Hangover: CROs, CDMOs and a Capacity Conundrum
“Excess capacity” – not a phrase one expects to hear in a high-growth industry riding on the coattails of pharmaceutical innovation.
In Praise of Discomfort: Why Less Government Funding Might Be Good for Science
There are few things more sacred in biotech than the sanctity of government grants. At the heart of this cathedral
Longevity Treatments in Human Trials (2024–2025)
The field of longevity therapeutics has rapidly progressed from animal studies to human clinical trials in recent years. Multiple approaches
Decentralized Science in Biomedicine: Trials, Tokens, and Tribulations
Introduction
A new breed of lab-coat-clad blockchain enthusiasts believes they can reinvent biomedical research. In decentralized science (“DeSci”), clinical trials
The Surrogate Marker Paradox in Chronic Disease
Why Many Interventions Improve a Biomarker Without Altering the Underlying Condition
Surrogate Markers vs True Outcomes
Clinical research often relies
Certified to Death (With Distinction)
The modern pharmaceutical and scientific job market, dear reader, has developed a peculiar affliction—no, not another variant, but something
Biotech’s Glass Cage: The Overton Window, the Asymmetric Risk Trap, and the Limits of Scientific Imagination
It is not often that the bounds of acceptable discourse are described in terms of architecture. Yet the Overton Window—
The Biotech Deck Drinking Game
10 Slides You'll Always See
If you've been pitched by more than three biotech startups in
